WNT signaling pathway inhibitors for treatments of disease
Compounds and compositions are provided as inhibitors of the Wnt/β-catenin pathway for the treatment of diseases that implicate the same.
1. A compound having formula (II):
wherein R 7 represents a substituent selected from the group consisting of substituted or unsubstituted-isoquinolin-3-yl, quinolin-2-yl, quinolin-3-yl, naphthyl, thiazolyl, isooxazolyl, benzothiazolyl, benzimidizolyl, benzopyronyl,
R 8 represents a substituent selected from the group consisting of H, OH, NO 2 , CN, halo, unsubstituted alkyl, and substituted or unsubstituted alkenyl, alkynyl, aryl, amino, and alkoxy;
R 9 , R 10 , R 11 , R 12 , and R 13 each can independently represent a substituent selected from the group consisting of H, OH, NO 2 , CN, halo, and substituted or unsubstituted alkyl, alkylcarbonyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfonamido, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl;
X 4 represents N or CR 14 ;
X 5 represents N;
R 14 independently represents a substituent selected from the group consisting of H, OH, NO 2 , CN, halo, and substituted or unsubstituted alkyl, alkylcarbonyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfonamido, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl or the pharmaceutically acceptable salts of the compound.
2. The compound of claim 1 , wherein the compound is 1-(2-Methoxyphenyl)-5-methyl-N-(quinolin-2-yl)-1H-1,2,3-triazole-4-carboxamide, or 5-Methyl-N-(quinolin-2-yl)-1-(o-tolyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein R 7 is selected from
4. The compound of claim 1 , wherein R 7 is selected from substituted or unsubstituted isoquinolin-3-yl, quinolin-2-yl, quinolin-3-yl.
5. The compound of claim 4 , wherein R 7 is selected from
6. The compound of claim 1 , wherein R 9 is selected from hydrogen, methyl, ethyl, fluoro, bromo, chloro, CN, methoxy, NO 2 , —C(O)CH 3 , —C(O)NH 2 , phenyl, and morpholinyl.